Form 4: Neogenomics Executive Warren Stone Receives Stock Options and Restricted Stock Units
SEC Form 4 Filing
Warren Stone, President & Chief Operating Officer of Neogenomics, reports the acquisition of stock options and restricted stock units, along with modifications to vesting schedules following his promotion.
Summary
- Warren Stone, the President & Chief Operating Officer of Neogenomics, filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
- On April 1, 2025, Stone was granted 94,518 stock options with an exercise price of $10.44, vesting ratably over 12, 18, and 24 months.
- He also received 52,687 restricted stock units (RSUs) vesting on the same schedule.
- The filing also notes modifications to the vesting schedules of previously granted stock options and RSUs from February 21, 2025, now vesting ratably over 12, 18, and 24 months due to his promotion.
- Stone directly owns 90,793 shares of Neogenomics common stock.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices, with incentives tied to company performance. This is generally viewed positively as it aligns management's interests with shareholders.
Positives
- The grant of stock options and RSUs aligns Stone's interests with those of shareholders.
- The vesting schedules encourage long-term commitment from the executive.
- Performance stock units incentivize the achievement of specific growth targets.
Risks
- The value of the stock options and RSUs is dependent on the future performance of Neogenomics' stock.
- Failure to meet performance targets could result in the PSUs not vesting fully.
Future Outlook
The vesting of performance stock units is contingent upon the achievement of certain share growth and revenue growth goals, indicating a focus on future performance.
Industry Context
Executive compensation packages including stock options and RSUs are common in the biotech industry to attract and retain talent, aligning their interests with shareholder value creation.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the diagnostics and biotechnology industries.
- Companies like Exact Sciences and Guardant Health also utilize stock options and RSUs to incentivize their executives.
- The vesting schedules and performance-based components are generally in line with industry practices to promote long-term value creation.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| President & Chief Operating Officer | N/A | Warren Stone | 04/01/2025 | Promotion |
Stakeholder Impact
- Shareholders: Aligns executive compensation with company performance, potentially increasing shareholder value.
- Employees: Provides insight into executive compensation structure.
- Executives: Provides details on compensation and equity ownership.
Key Dates
| Date | Description |
|---|---|
| 12/01/2022 | Mr. Stone was granted 166,113 stock options. |
| 05/11/2023 | Mr. Stone was granted 53,969 stock options and 28,838 restricted stock units. |
| 02/23/2024 | Mr. Stone was granted 42,344 stock options and 25,329 restricted stock units. |
| 05/02/2024 | Mr. Stone was granted 29,976 stock options and 17,905 restricted stock units. |
| 02/21/2025 | Mr. Stone was granted 143,266 stock options and 84,317 restricted stock units. |
| 04/01/2025 | Date of earliest transaction reported; Mr. Stone's promotion to President & Chief Operating Officer; Grant date of 94,518 stock options and 52,687 restricted stock units. |
| 04/03/2025 | Date of Form 4 filing. |
| 05/11/2026 | Performance Stock Unit Expiration Date |
| 02/23/2027 | Performance Stock Unit Expiration Date |
| 05/02/2027 | Performance Stock Unit Expiration Date |
| 12/01/2029 | Stock Option Expiration Date |
| 05/11/2030 | Stock Option Expiration Date |
| 02/23/2034 | Stock Option Expiration Date |
| 05/02/2034 | Stock Option Expiration Date |
| 02/21/2035 | Stock Option Expiration Date |
| 04/01/2035 | Stock Option Expiration Date |
Keywords
Neogenomics, Warren Stone, stock options, restricted stock units, Form 4, beneficial ownership, vesting, executive compensation, performance stock units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.